A former Pfizer employee is being charged with insider trading for allegedly attempting to profit off the pharmaceutical giant’s treatment for COVID-19.
June 29 A former Pfizer employee is being charged with insider trading for allegedly attempting to profit off the pharmaceutical giant’s treatment for COVID-19.
Former statistician Amit Dagar attempted to make financial gains from the company’s Paxlovid antiviral drug, before it became publicly known that the treatment had passed an important clinical trial, the U.S. Securities and Exchange Commission said on Thursday.
Dagar’s business partner Atul Bhiwapurkar was also charged.
Pfizer announced in November of 2021 that Paxlovid had passed a double-blind clinical trial, which had started in July of that year.
